Beyond business as usual for lymphatic filariasis mass drug administration in hotspot districts.

IF 2.2 4区医学 Q2 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

International Health Pub Date : 2025-04-12 DOI:10.1093/inthealth/ihaf039

Dziedzom K de Souza, Jeffrey G Sumboh, Nii A Laryea, Odame Asiedu, Bright Alomatu, Sedzro K Mensah, Joseph Otchere, Joseph Larbi Opare, Collins S Ahorlu

{"title":"Beyond business as usual for lymphatic filariasis mass drug administration in hotspot districts.","authors":"Dziedzom K de Souza, Jeffrey G Sumboh, Nii A Laryea, Odame Asiedu, Bright Alomatu, Sedzro K Mensah, Joseph Otchere, Joseph Larbi Opare, Collins S Ahorlu","doi":"10.1093/inthealth/ihaf039","DOIUrl":null,"url":null,"abstract":"Background: This study aimed to validate the 'Engage & Treat' (E&T) and 'Test & Treat' (T&T) strategies to treat individuals who seldom or never participate in lymphatic filariasis mass drug administration (LF MDA).Methods: The study was conducted in a hotspot district of Ghana, with 20 years of MDA. Treatment registers documenting participation were used to identify non-participating individuals. Individuals willingly accepting treatment were given the drugs (E&T). Those who refused treatment were offered testing using the filaria test strip (FTS) and further engaged to receive treatment if positive (T&T). A portion of the E&T participants were also tested.Results: Overall, 25 068 individuals who missed the last MDA were identified; 93.13% accepted the drugs; 9958 people were tested, revealing an overall prevalence of 7.26% (95% CI 6.76 to 7.79%). Positivity was higher in T&T (12.10%; 95% CI 10.43 to 13.92%) than in the E&T group (6.47%; 95% CI 5.96 to 7.01%). The odds of testing positive were higher (OR=1.99; 95% CI 1.66 to 2.39; p<0.0001) among the T&T population and missing three consecutive MDAs (OR=2.22; 95% CI 1.86 to 2.64; p<0.0001).Conclusions: The study confirms the validity of the strategies in addressing the challenges with non-treatment during LF MDA. Their implementation in areas of persistent transmission can support elimination in these settings.","PeriodicalId":49060,"journal":{"name":"International Health","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/inthealth/ihaf039","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aimed to validate the 'Engage & Treat' (E&T) and 'Test & Treat' (T&T) strategies to treat individuals who seldom or never participate in lymphatic filariasis mass drug administration (LF MDA).

Methods: The study was conducted in a hotspot district of Ghana, with 20 years of MDA. Treatment registers documenting participation were used to identify non-participating individuals. Individuals willingly accepting treatment were given the drugs (E&T). Those who refused treatment were offered testing using the filaria test strip (FTS) and further engaged to receive treatment if positive (T&T). A portion of the E&T participants were also tested.

Results: Overall, 25 068 individuals who missed the last MDA were identified; 93.13% accepted the drugs; 9958 people were tested, revealing an overall prevalence of 7.26% (95% CI 6.76 to 7.79%). Positivity was higher in T&T (12.10%; 95% CI 10.43 to 13.92%) than in the E&T group (6.47%; 95% CI 5.96 to 7.01%). The odds of testing positive were higher (OR=1.99; 95% CI 1.66 to 2.39; p<0.0001) among the T&T population and missing three consecutive MDAs (OR=2.22; 95% CI 1.86 to 2.64; p<0.0001).

Conclusions: The study confirms the validity of the strategies in addressing the challenges with non-treatment during LF MDA. Their implementation in areas of persistent transmission can support elimination in these settings.

查看原文本刊更多论文

在热点地区淋巴丝虫病的大规模药物管理工作之外。

背景：本研究旨在验证“参与与治疗”（Engage & Treat, E&T）和“测试与治疗”（Test & Treat, T&T）策略对很少或从未参与淋巴丝虫病大规模给药（LF MDA）的个体的治疗效果。方法：研究在加纳的一个热点地区进行，MDA为20年。使用记录参与情况的治疗登记册来识别未参与的个体。自愿接受治疗的个体被给予药物（E&T）。拒绝治疗的患者使用丝虫病试纸（FTS）进行检测，如果呈阳性则进一步接受治疗。一部分E&T参与者也接受了测试。结果：总的来说，25 068人错过了最后一个MDA；接受药品的占93.13%；9958人接受了检测，显示总体患病率为7.26% （95% CI 6.76至7.79%）。T&T阳性率较高(12.10%；95% CI 10.43 - 13.92%)高于E&T组(6.47%；95% CI 5.96 ~ 7.01%)。检测阳性的几率较高(OR=1.99；95% CI 1.66 ~ 2.39；结论：该研究证实了这些策略在解决LF MDA期间未治疗的挑战方面的有效性。在持续传播地区实施这些措施可支持在这些环境中消除疾病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Health PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-

CiteScore

4.50

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： International Health is an official journal of the Royal Society of Tropical Medicine and Hygiene. It publishes original, peer-reviewed articles and reviews on all aspects of global health including the social and economic aspects of communicable and non-communicable diseases, health systems research, policy and implementation, and the evaluation of disease control programmes and healthcare delivery solutions. It aims to stimulate scientific and policy debate and provide a forum for analysis and opinion sharing for individuals and organisations engaged in all areas of global health.